Literature DB >> 31916447

Differential microRNA-21 and microRNA-221 Upregulation in the Biventricular Failing Heart Reveals Distinct Stress Responses of Right Versus Left Ventricular Fibroblasts.

Jeffery C Powers1, Abdelkarim Sabri1, Dalia Al-Bataineh1, Dhruv Chotalia1, Xinji Guo1, Florence Tsipenyuk1, Remus Berretta1, Pavithra Kavitha1, Heramba Gopi1, Steven R Houser1, Mohsin Khan2, Emily J Tsai1,3, Fabio A Recchia1,4.   

Abstract

BACKGROUND: The failing right ventricle (RV) does not respond like the left ventricle (LV) to guideline-directed medical therapy of heart failure, perhaps due to interventricular differences in their molecular pathophysiology.
METHODS: Using the canine tachypacing-induced biventricular heart failure (HF) model, we tested the hypothesis that interventricular differences in microRNAs (miRs) expression distinguish failing RV from failing LV.
RESULTS: Severe RV dysfunction was indicated by elevated end-diastolic pressure (11.3±2.5 versus 5.7±2.0 mm Hg; P<0.0001) and diminished fractional area change (24.9±7.1 versus 48.0±3.6%; P<0.0001) relative to prepacing baselines. Microarray analysis of ventricular tissue revealed that miR-21 and miR-221, 2 activators of profibrotic and proliferative processes, increased the most, at 4- and 2-fold, respectively, in RV-HF versus RV-Control. Neither miR-21 or miR-221 was statistically significantly different in LV-HF versus LV-Control. These changes were accompanied by more extensive fibrosis in RV-HF than LV-HF. To test whether miR-21 and miR-221 upregulation is specific to RV cellular response to mechanical and hormonal stimuli associated with HF, we subjected fibroblasts and cardiomyocytes isolated from normal canine RV and LV to cyclic overstretch and aldosterone. These 2 stressors markedly upregulated miR-21 and miR-221 in RV fibroblasts but not in LV fibroblasts nor cardiomyocytes of either ventricle. Furthermore, miR-21/221 knockdown significantly attenuated RV but not LV fibroblast proliferation.
CONCLUSIONS: We identified a novel, biological difference between RV and LV fibroblasts that might underlie distinctions in pathological remodeling of the RV in biventricular HF.

Entities:  

Keywords:  aldosterone; fibroblasts; heart failure; microarray analysis; upregulation

Mesh:

Substances:

Year:  2020        PMID: 31916447      PMCID: PMC7006717          DOI: 10.1161/CIRCHEARTFAILURE.119.006426

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  15 in total

1.  Early right ventriculo-arterial uncoupling in borderline pulmonary hypertension on experimental heart failure.

Authors:  Alberto Pagnamenta; Céline Dewachter; Kathleen McEntee; Pierre Fesler; Serge Brimioulle; Robert Naeije
Journal:  J Appl Physiol (1985)       Date:  2010-08-05

2.  Diversity, topographic differentiation, and positional memory in human fibroblasts.

Authors:  Howard Y Chang; Jen-Tsan Chi; Sandrine Dudoit; Chanda Bondre; Matt van de Rijn; David Botstein; Patrick O Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-24       Impact factor: 11.205

3.  Animal model of reversible, right ventricular failure.

Authors:  Stephen H McKellar; Hadi Javan; Megan E Bowen; Xiaoquing Liu; Christin L Schaaf; Casey M Briggs; Huashan Zou; Arnold David Gomez; Osama M Abdullah; Ed W Hsu; Craig H Selzman
Journal:  J Surg Res       Date:  2014-11-10       Impact factor: 2.192

Review 4.  MicroRNAs in right ventricular remodelling.

Authors:  Sandor Batkai; Christian Bär; Thomas Thum
Journal:  Cardiovasc Res       Date:  2017-10-01       Impact factor: 10.787

5.  RV Longitudinal Deformation Correlates With Myocardial Fibrosis in Patients With End-Stage Heart Failure.

Authors:  Matteo Lisi; Matteo Cameli; Francesca Maria Righini; Angela Malandrino; Damiana Tacchini; Marta Focardi; Charilaos Tsioulpas; Sonia Bernazzali; Piero Tanganelli; Massimo Maccherini; Sergio Mondillo; Michael Y Henein
Journal:  JACC Cardiovasc Imaging       Date:  2015-04-15

6.  MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overload-Induced Heart Failure.

Authors:  Robin Verjans; Tim Peters; Francisco Javier Beaumont; Rick van Leeuwen; Tessa van Herwaarden; Wouter Verhesen; Chantal Munts; Mitchell Bijnen; Michiel Henkens; Javier Diez; Leon J de Windt; Frans A van Nieuwenhoven; Marc van Bilsen; Marie José Goumans; Stephane Heymans; Arantxa González; Blanche Schroen
Journal:  Hypertension       Date:  2017-12-18       Impact factor: 10.190

7.  Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.

Authors:  Lena Bosch; Carolyn S P Lam; Lingli Gong; Siew Pang Chan; David Sim; Daniel Yeo; Fazlur Jaufeerally; Kui Toh Gerard Leong; Hean Yee Ong; Tze Pin Ng; Arthur Mark Richards; Fatih Arslan; Lieng H Ling
Journal:  Eur J Heart Fail       Date:  2017-06-08       Impact factor: 15.534

8.  Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure.

Authors:  Sushma Reddy; Mingming Zhao; Dong-Qing Hu; Giovanni Fajardo; Shijun Hu; Zhumur Ghosh; Viswanathan Rajagopalan; Joseph C Wu; Daniel Bernstein
Journal:  Physiol Genomics       Date:  2012-03-27       Impact factor: 3.107

9.  Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy.

Authors:  Felix Woitek; Lorena Zentilin; Nicholas E Hoffman; Jeffery C Powers; Isabel Ottiger; Suraj Parikh; Anna M Kulczycki; Marykathryn Hurst; Nadja Ring; Tao Wang; Farah Shaikh; Polina Gross; Harinder Singh; Mikhail A Kolpakov; Axel Linke; Steven R Houser; Victor Rizzo; Abdelkarim Sabri; Muniswamy Madesh; Mauro Giacca; Fabio A Recchia
Journal:  J Am Coll Cardiol       Date:  2015-07-14       Impact factor: 24.094

10.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts.

Authors:  Thomas Thum; Carina Gross; Jan Fiedler; Thomas Fischer; Stephan Kissler; Markus Bussen; Paolo Galuppo; Steffen Just; Wolfgang Rottbauer; Stefan Frantz; Mirco Castoldi; Jürgen Soutschek; Victor Koteliansky; Andreas Rosenwald; M Albert Basson; Jonathan D Licht; John T R Pena; Sara H Rouhanifard; Martina U Muckenthaler; Thomas Tuschl; Gail R Martin; Johann Bauersachs; Stefan Engelhardt
Journal:  Nature       Date:  2008-11-30       Impact factor: 49.962

View more
  6 in total

1.  Application of Combined Detection of Echocardiography and Serum NT-ProBNP in the Diagnosis of Diastolic Heart Failure and Its Effect on Left Ventricular Morphology and Diastolic Function.

Authors:  Wei Yang; Zhonghua Zhang; Defeng Liang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-24       Impact factor: 2.650

Review 2.  Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Sasha Z Prisco; Thenappan Thenappan; Kurt W Prins
Journal:  JACC Basic Transl Sci       Date:  2020-12-28

Review 3.  Non-coding RNAs: Important participants in cardiac fibrosis.

Authors:  Yiheng Dong; Naling Peng; Lini Dong; Shengyu Tan; Xiangyu Zhang
Journal:  Front Cardiovasc Med       Date:  2022-07-28

4.  Progress in research on the role of exosomal miRNAs in the diagnosis and treatment of cardiovascular diseases.

Authors:  Jinyu Xu; Weitie Wang; Yong Wang; Zhicheng Zhu; Dan Li; Tiance Wang; Kexiang Liu
Journal:  Front Genet       Date:  2022-10-04       Impact factor: 4.772

Review 5.  Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches.

Authors:  Begoña López; Susana Ravassa; María U Moreno; Gorka San José; Javier Beaumont; Arantxa González; Javier Díez
Journal:  Nat Rev Cardiol       Date:  2021-02-10       Impact factor: 32.419

Review 6.  Adaptive and innate immune mechanisms in cardiac fibrosis complicating pulmonary arterial hypertension.

Authors:  Jamila H Siamwala; Alexander Zhao; Haley Barthel; Francesco S Pagano; Richard J Gilbert; Sharon Rounds
Journal:  Physiol Rep       Date:  2020-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.